SCHEMBL4698629

SCHEMBL4698629

CN1C(=O)CN(C(=O)OC(C)(C)C)C(=O)c2ccccc21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 2/20 0.46
HDAC6 Q9UBN7 2/20 0.46
BCHE P06276 1/20 0.42
KDM1A O60341 1/20 0.41
TTR P02766 1/20 0.40
CES1 P23141 1/20 0.40
NOTUM Q6P988 1/20 0.39
MTOR P42345 3/20 0.39
TRPA1 O75762 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
GABRA1 P14867 1/20 0.37
GABRG2 P18507 1/20 0.37
GABRB3 P28472 1/20 0.37
GABRA5 P31644 1/20 0.37
CCKBR P32239 1/20 0.37
GABRA3 P34903 1/20 0.37
GABRA2 P47869 1/20 0.37
GABRB2 P47870 1/20 0.37
ALDH1A1 P00352 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7086781 0.80 TTR (0.46) HDAC1HDAC6TTRCES1NOTUM
SCHEMBL29814717 0.79 KDM4E (0.51) HDAC1HDAC6BCHEKDM1AMTOR
SCHEMBL23771943 0.79 KDM4E (0.51) HDAC1HDAC6BCHEKDM1AMTOR
SCHEMBL3429052 0.77 MAPK1 (0.51) HDAC1HDAC6BCHEKDM1AMAPK1
SCHEMBL6006023 0.77 HDAC1 (0.43) HDAC1HDAC6MTORALDH1A1KMT2A
SCHEMBL7004709 0.76 NOTUM (0.64) HDAC1HDAC6BCHEKDM1ANOTUM
SCHEMBL30667212 0.76 NOTUM (0.64) HDAC1HDAC6BCHEKDM1ANOTUM
SCHEMBL13502703 0.75 KDM4E (0.47) HDAC1HDAC6BCHEKDM1ANOTUM
SCHEMBL4701494 0.74 HDAC6 (0.41) HDAC1HDAC6ALDH1A1KMT2A
SCHEMBL31330330 0.72 STS (0.40) HDAC1HDAC6NOTUMKMT2APDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1326849-B1 BENZODIAZEPINE DERIVATIVES AS INHIBITORS OF GAMMA SECRETASE MERCK SHARP & DOHME (GB) 2008-07-16 EP disclosed
US-7105509-B2 Benzodiazepine derivatives as APP modulators MERCK SHARP & DOHME LIMITED (GB) 2006-09-12 US disclosed
US-6995155-B2 Benzodiazepine derivatives as inhibitors of gamma secretase MERCK SHARP & DOHME LIMITED (GB) 2006-02-07 US disclosed
US-20040082572-A1 Benzodiazepine derivatives as app modulators MERCK SHARPE & DOHME LIMITED (GB) 2004-04-29 US disclosed
US-20040024203-A1 Benzodiazepine derivatives as inhibitors of gamma secretase MERCK SHARP & DOHME LTD. (GB) 2004-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082572-A1 Benzodiazepine derivatives as app modulators BACE1, PSEN1, APP HDAC1 1348/4885HDAC6 2776/4885BCHE 394/4885
US-20040024203-A1 Benzodiazepine derivatives as inhibitors of gamma secretase BACE1, BACE2, PSEN1 HDAC1 452/4885HDAC6 1236/4885BCHE 62/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.